Abstract
A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis.
René Westhovens, Frédéric Houssiau, Johan Joly, Daniel E Everitt, Yaowei Zhu, Deborah Sisco, Bart Van Hartingsveldt, Mary Ann Mascelli, Martin A Graham, Patrick Durez and Esther Bouman-Thio
The Journal of Rheumatology May 2006, 33 (5) 847-853;
René Westhovens
Frédéric Houssiau
Johan Joly
Daniel E Everitt
Yaowei Zhu
Deborah Sisco
Bart Van Hartingsveldt
Mary Ann Mascelli
Martin A Graham
Patrick Durez
In this issue
The Journal of Rheumatology
Vol. 33, Issue 5
1 May 2006
A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis.
René Westhovens, Frédéric Houssiau, Johan Joly, Daniel E Everitt, Yaowei Zhu, Deborah Sisco, Bart Van Hartingsveldt, Mary Ann Mascelli, Martin A Graham, Patrick Durez, Esther Bouman-Thio
The Journal of Rheumatology May 2006, 33 (5) 847-853;
A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis.
René Westhovens, Frédéric Houssiau, Johan Joly, Daniel E Everitt, Yaowei Zhu, Deborah Sisco, Bart Van Hartingsveldt, Mary Ann Mascelli, Martin A Graham, Patrick Durez, Esther Bouman-Thio
The Journal of Rheumatology May 2006, 33 (5) 847-853;